# Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

> **NCT00304954** · PHASE2 · COMPLETED · sponsor: **National Eye Institute (NEI)** · enrollment: 13 (actual)

## Conditions studied

- Age-Related Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** Intravenous Daclizumab
- **DRUG:** Intravenous Infliximab
- **OTHER:** Observation
- **DRUG:** Oral Rapamycin

## Key facts

- **NCT ID:** NCT00304954
- **Lead sponsor:** National Eye Institute (NEI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00304954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00304954, "Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00304954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*